Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Dermavant Sciences has shared positive long-term results for its plaque psoriasis-approved Vtama (tapinarof) cream in adults and children as young as two years old with atopic dermatitis (AD).

Jersey City-based Organon has completed its acquisition of Dermavant Sciences Ltd. from Roivant. Dermavant is a company ...

With the deal's closure, Organon has added Dermavant’s VTAMA (tapinarof) cream 1%, a US Food and Drug Administration ...

VTAMA ® (tapinarof) cream, 1%, is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug Administration (FDA) for treatment of mild, moderate, and severe plaque ...

Update on FDA Review of VTAMA® (tapinarof ... management’s expectations regarding Organon’s recent acquisition of Dermavant Sciences Ltd. (“Dermavant”) and potential regulatory approval ...

Analysts project VTAMA's sales potential to reach $500 million or more, contingent upon successful pediatric market penetration and patients switching from topical steroids. The recent acquisition of ...

“The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands and ...

Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology. VTAMA cream, 1%, is a novel nonbiologic, non-steroidal topical therapy ...